IN Brief:
- Movianto’s five-year NHS England contract covers an end-to-end vaccine logistics network serving more than 11,000 locations.
- The operation combines storage, inventory management, fulfilment, sortation, and GDP-compliant temperature-controlled distribution.
- NHS England is using Movianto’s existing shared healthcare logistics infrastructure rather than creating a dedicated parallel network.
Movianto UK has started a five-year NHS England contract covering vaccine storage, inventory management, order fulfilment, sortation, and GDP-compliant temperature-controlled distribution to more than 11,000 healthcare locations across England.
The national contract went live in August after a competitive tender process and has an award value of £34.22 million excluding VAT. It supports vaccination, immunisation, and screening programmes across frontline destinations including general practices, community pharmacies, detained estates, and other healthcare settings.
Rather than creating a separate warehouse and transport network solely for NHS England, Movianto is using its existing regulated healthcare infrastructure. Suppliers can move products into the shared network, where inventory is stored and orders are fulfilled before temperature-controlled distribution to healthcare providers.
The shared-user model changes the amount of physical duplication built into the programme. Dedicated facilities can provide clear separation, but they also create additional stock transfers, spare capacity, and duplicated transport resources when demand varies. Using an established pharmaceutical network allows the operator to flex storage and distribution alongside other healthcare activity, subject to the segregation and quality controls required for vaccines.
Those controls are central to the contract. Vaccine logistics requires traceability by batch and product, validated storage conditions, accurate inventory, and delivery within defined temperature ranges. A missed delivery or temperature excursion can prevent doses being used even where the wider transport network is operating normally.
Movianto’s UK operation already has experience with national vaccination programmes and emergency response. During the Covid-19 rollout it handled central storage and distribution for vaccines with demanding temperature requirements, while its routine work has included childhood and seasonal vaccination programmes.
The new contract puts that capability into a longer-term operating framework rather than an emergency mobilisation. NHS England has commissioned an end-to-end supply chain service, making the provider responsible for how storage, stock control, fulfilment, and transport perform together across more than 11,000 destinations.
A July mobilisation for the Meningococcal Group B vaccination programme provided an early test. Movianto says more than 16,000 orders had been processed and delivered as the network scaled activity for community pharmacies and other vaccination providers. The exercise required additional capacity to be brought into the system at short notice.
Surge performance is one of the harder requirements in healthcare logistics because demand can change faster than a dedicated network can be resized. Routine immunisation volumes can be forecast with reasonable accuracy, but outbreaks, new programme decisions, or emergency public-health responses can create sudden regional or national demand.
Shared infrastructure gives Movianto access to warehouse, labour, and transport resources already operating across pharmaceutical supply chains. That can reduce the amount of idle capacity NHS England would otherwise need to fund purely as contingency. The model also creates a competing requirement: spare capacity has to remain genuinely available when several healthcare customers experience peaks at the same time.
Inventory visibility becomes critical under that structure. Vaccines have expiry dates, different storage conditions, and programme-specific allocations, so stock cannot be treated as a generic pool simply because it sits in a multi-user warehouse. The operator needs to maintain product integrity and programme ownership while still using common infrastructure efficiently.
The contract also carries a transport-efficiency objective. Moving supplier stock directly into Movianto’s regulated storage network can remove intermediate transfers between facilities before final distribution, reducing handling and vehicle movements. Fewer hand-offs can lower cost and emissions, but they also reduce the number of points at which a shipment can be delayed or exposed to temperature risk.
Movianto became part of Yusen Logistics in 2025, giving the healthcare specialist access to a wider international logistics group while retaining its regulated pharmaceutical network. The current European operation spans 23 pharmaceutical distribution centres across 11 countries, with services covering warehousing, order fulfilment, transport, customs, and other healthcare supply chain functions.
The five-year term means performance will be tested across several seasonal cycles rather than a single launch. Inventory accuracy, on-time delivery, temperature compliance, and the ability to absorb emergency demand will determine whether the shared-user approach produces the resilience and efficiency promised at award.
National vaccine distribution leaves little room for a cosmetic logistics improvement. The programme can tolerate neither uncontrolled cost nor compromised product condition, and a network serving more than 11,000 destinations will expose weak processes quickly. Movianto now has the contract, the existing infrastructure, and the previous mobilisation experience; the next five years will show how well those elements hold together under routine and exceptional demand.
